153 related articles for article (PubMed ID: 11189737)
1. FDA approves Trizivir for HIV infection.
AIDS Read; 2000 Dec; 10(12):701. PubMed ID: 11189737
[No Abstract] [Full Text] [Related]
2. Trizivir on the market.
Kerr C
Trends Microbiol; 2001 Jan; 9(1):13. PubMed ID: 11166234
[No Abstract] [Full Text] [Related]
3. Anti-HIV agents. Trizivir--three drugs in one pill.
TreatmentUpdate; 2000 Feb; 12(1):1-2. PubMed ID: 12125625
[No Abstract] [Full Text] [Related]
4. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
Porche D
J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
[TBL] [Abstract][Full Text] [Related]
5. AIDS foundation seeks withdrawal of approval for HIV drug combination.
Clarke B
Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
[No Abstract] [Full Text] [Related]
6. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
[No Abstract] [Full Text] [Related]
7. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
Seaton RA; Fox R; Bodasing N; Peters SE; Gourlay Y
AIDS; 2003 Feb; 17(3):445-7. PubMed ID: 12556701
[No Abstract] [Full Text] [Related]
8. Triple-drug tablet approved for HIV infection.
Thompson CA
Am J Health Syst Pharm; 2001 Jan; 58(1):22. PubMed ID: 11194130
[No Abstract] [Full Text] [Related]
9. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
Feinberg J
AIDS Clin Care; 2003 Sep; 15(9):78-9. PubMed ID: 14669723
[TBL] [Abstract][Full Text] [Related]
10. New formulations approved for children.
AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
[No Abstract] [Full Text] [Related]
11. From the food and drug administration.
Henney JE
JAMA; 2001 Jan; 285(1):34. PubMed ID: 11150092
[No Abstract] [Full Text] [Related]
12. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J
HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326
[No Abstract] [Full Text] [Related]
13. Trizivir approved in Canada.
TreatmentUpdate; 2001; 13(7):1. PubMed ID: 11794856
[No Abstract] [Full Text] [Related]
14. We want our Trizivir!
Vázquez E
Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938
[No Abstract] [Full Text] [Related]
15. FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
AIDS Alert; 2009 Feb; 24(2):22. PubMed ID: 19219952
[No Abstract] [Full Text] [Related]
16. Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
Shaefer MS
Ann Pharmacother; 2004; 38(7-8):1314-6. PubMed ID: 15187204
[No Abstract] [Full Text] [Related]
17. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
[No Abstract] [Full Text] [Related]
18. Anatomy of a study: Trizivir vs. Sustiva.
Berger DS
Posit Aware; 2003; 14(3):40-1. PubMed ID: 12866492
[No Abstract] [Full Text] [Related]
19. [Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Valencia ME; Moreno V
Rev Clin Esp; 2012 Jan; 212(1):26-30. PubMed ID: 21839993
[TBL] [Abstract][Full Text] [Related]
20. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
